18 May 2022
Embrace the innovation in PCI and TAVR: Robocath R-One vascular robot for PCI in China, MicroPort Firehawk TES stent, and VitaFlow valve
Sponsored by MicroPort
Anchorperson:
A. Baumbach
Moderator:
P. Smits
Summary
The objective of this EuroPCR 2022 session is to highlight MicroPort's innovation portfolio in 3 different fields: learn more about the clinical performance of Firehawk Family stent in STEMI patients evaluated by imaging tools, the features and benefits of PCI robot R-ONE and first clinical trial updates in China, and the five-year clinical results of VitaFlow Transcatheter Aortic Valve System.
Learning Objectives
- To learn the clinical performance of Firehawk Family stent in STEMI patients evaluated by imaging tools
- To learn the features and benefits of PCI robot R-ONE and first clinical trial updates in China
- To learn the five-year clinical results of VitaFlow Transcatheter Aortic Valve System
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)